Lupin receives USFDA nod for injectable used to treat Schizophrenia and bipolar disorder

Lupin said this is its first product using proprietary Nanomi B.V.’s (Nanomi) technology and has a 180-day CGT exclusivity.

Leave a Reply

Your email address will not be published. Required fields are marked *